- $418.66m
- $160.35m
- 36
- 33
- 56
- 36
Annual balance sheet for Tourmaline Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 149 | 244 | 181 | 203 | 258 |
| Net Total Receivables | 0.374 | — | — | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 151 | 247 | 186 | 209 | 269 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.01 | 4.8 | 7.99 | 0.57 | 0.267 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 153 | 251 | 194 | 210 | 309 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.4 | 7.99 | 11.5 | 5 | 8.91 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.77 | 8.61 | 13.7 | 5.25 | 8.95 |
| Redeemable Preferred Stock | |||||
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 148 | 243 | 180 | 205 | 300 |
| Total Liabilities & Shareholders' Equity | 153 | 251 | 194 | 210 | 309 |
| Total Common Shares Outstanding |